On 1 September, Vitality Group International, the US subsidiary of Discovery, completed the purchase of Icario Holdco, a US company that builds digital tools to keep members of government-funded health plans engaged. The transaction was paid for in cash, $27 million up front, and includes a contingent component that could add another $32.5 million if Icario meets revenue targets and delivers growth in its annual recurring contracts.
According to the company, the contingent payment is an “earn-out”, a common mechanism where the seller receives extra money only if the business hits agreed-upon performance milestones after the sale. The deal was closed on a debt-free, cash-free basis, meaning Icario did not bring any debt or cash into the transaction.
Because the acquisition closed after Discovery’s financial year ended on 30 June, none of Icario’s revenue or profit appears in the group’s recently released results. The purchase price allocation, the accounting process that splits the total price into assets, goodwill and other items, remains provisional. Discovery said it will use a multi-period excess earnings model, a method that values intangible assets such as customer relationships based on the future cash flows they are expected to generate.
What the acquisition means for Discovery and the market
Icario serves roughly 11 million lives, primarily through Medicaid, Medicare Advantage and Dual Eligible Special Needs plans, US government-sponsored health programmes. By adding Icario’s engagement platform to its Vitality behavioural ecosystem, Discovery aims to strengthen “member activation, engagement and health plan capabilities” and to open cross-selling opportunities for its other products.
The move follows a series of US-focused purchases. In November 2024 VitalityHealth USA bought workplace-wellness firm WellSpark, and in March 2026 it acquired Ramp Health. A partnership with HealthEquity, the largest custodian of health savings accounts in the US, also went live earlier this year. Together, these steps have expanded the unit’s footprint to ten health plans and 3.6 million covered members, with revenue growth of 22 percent over the year.
Discovery is also extending its AI-driven health-tech push to Asia. Through Amplify Health, a joint venture in which Discovery holds a 25 percent stake alongside AIA, the group has signed a three-year deal with Star Health in India to deploy AI-led claims intelligence and analytics. The company describes these products as “integrated solutions with multi-year value-share economics” in four key markets.
Back in South Africa, the AI focus is already reflected in the financials. Vitality AI, the platform that powers the AI-enabled engagement tools, recorded a loss of R299 million in FY2026, more than double the previous year’s figure. Discovery notes that the loss includes broader Vitality central costs, not just the AI unit.
For South African insurers, health-tech startups and corporate wellness providers, the acquisition signals a clear intent from a major player to embed AI and data analytics into member engagement at scale. While the immediate financial impact on Discovery’s balance sheet is modest, the strategic emphasis on AI could raise the bar for local firms that wish to partner with or compete against the group’s expanding ecosystem.
The earn-out structure used here is common in health-tech acquisitions specifically because platforms like Icario are valued heavily on future growth rather than current earnings. Buyers use a multi-period excess earnings model to isolate what a customer relationship or a piece of software is worth on its own, separate from goodwill, precisely so that a contingent payment can be tied to real, measurable performance rather than a guess made at signature. For a listed group like Discovery, structuring a deal this way limits downside risk on its own balance sheet if Icario’s government-plan contracts underperform, while still giving the seller a path to a higher total price if they do not.
The broader pattern, five US acquisitions and partnerships in under two years, points to Discovery treating its American Vitality business as the group’s primary growth engine outside its home market, at a time when South Africa’s insurance sector overall is maturing and growth increasingly has to be found offshore. Government-funded health plans in the US, Medicaid and Medicare Advantage in particular, are a large and comparatively stable market precisely because enrolment is driven by policy rather than discretionary consumer spending, which is likely part of why Discovery keeps returning to that segment rather than the more competitive commercial insurance market.
